We are proud to announce that our CEO, Christer Nordstedt, will present Oblique Therapeutics activities at Redeye, January 16, 2024. The head of research, Olof Larsson CSO, and Jonas Ekblom, Chair of the Board, will also present and answer questions during the event.
Please contact our CFO at mats.jonasson@obliquet.com for more information.